Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II maintenance GDC-0449 vs placebo in ovarian cancer (2nd/3rd complete remission)
2008-003789-24Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer comparing GDC-0449 maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival (hazard ratio). Started Oct 2008; status: completed.
02
Drugs
vismodegib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2008-003789-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003789-24.